These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
461 related articles for article (PubMed ID: 16458131)
1. The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis. Glaser R; Glick HA; Herrmann HC; Kimmel SE J Am Coll Cardiol; 2006 Feb; 47(3):529-37. PubMed ID: 16458131 [TBL] [Abstract][Full Text] [Related]
2. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. Stone GW; Bertrand ME; Moses JW; Ohman EM; Lincoff AM; Ware JH; Pocock SJ; McLaurin BT; Cox DA; Jafar MZ; Chandna H; Hartmann F; Leisch F; Strasser RH; Desaga M; Stuckey TD; Zelman RB; Lieber IH; Cohen DJ; Mehran R; White HD; JAMA; 2007 Feb; 297(6):591-602. PubMed ID: 17299194 [TBL] [Abstract][Full Text] [Related]
3. Platelet glycoprotein IIb/IIIa inhibitor use during percutaneous coronary intervention: IIb or Not IIb, what is the question? Young JJ; Kereiakes DJ J Invasive Cardiol; 2002 Jul; 14(7):404-10. PubMed ID: 12082194 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes. Boersma E J Am Coll Cardiol; 2007 Jan; 49(2):276; author reply 277. PubMed ID: 17222743 [No Abstract] [Full Text] [Related]
9. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Adgey AA Am Heart J; 1998 Apr; 135(4):S43-55. PubMed ID: 9539495 [TBL] [Abstract][Full Text] [Related]
10. Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE). Tricoci P; Peterson ED; Chen AY; Newby LK; Harrington RA; Greenbaum AB; Cannon CP; Gibson CM; Hoekstra JW; Pollack CV; Ohman EM; Gibler WB; Roe MT Am J Cardiol; 2007 May; 99(10):1389-93. PubMed ID: 17493466 [TBL] [Abstract][Full Text] [Related]
11. Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials. Tricoci P; Newby LK; Hasselblad V; Kong DF; Giugliano RP; White HD; Théroux P; Stone GW; Moliterno DJ; Van de Werf F; Armstrong PW; Prabhakaran D; Rasoul S; Bolognese L; Durand E; Braunwald E; Califf RM; Harrington RA Circ Cardiovasc Qual Outcomes; 2011 Jul; 4(4):448-58. PubMed ID: 21712522 [TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing. Hobbach HP; Schuster P Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467 [TBL] [Abstract][Full Text] [Related]
13. Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes. Plosker GL; Ibbotson T Pharmacoeconomics; 2003; 21(12):885-912. PubMed ID: 12908844 [TBL] [Abstract][Full Text] [Related]
14. Use of glycoprotein IIb/IIIa inhibitors in invasively-treated patients with non-ST elevation acute coronary syndrome. De Servi S; Mariani M; Vandoni P; Dellavalle A; Politi A; Poletti F; Bonizzoni E; Leoncinie M; J Cardiovasc Med (Hagerstown); 2006 Mar; 7(3):159-65. PubMed ID: 16645379 [TBL] [Abstract][Full Text] [Related]
15. Long-term results following switch from abciximab to eptifibatide during percutaneous coronary intervention. Koutouzis M; Lagerqvist B; Oldgren J; Akerblom A; Wahlin M; Karlsson T; Albertsson P; Matejka G; Grip L Clin Cardiol; 2010 Nov; 33(11):686-92. PubMed ID: 21089113 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of antithrombotic therapy in nonurgent percutaneous coronary intervention. Summers KM; Holdford DA; Crouch MA Pharmacotherapy; 2006 May; 26(5):609-18. PubMed ID: 16637790 [TBL] [Abstract][Full Text] [Related]
18. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial. Bolognese L; Falsini G; Liistro F; Angioli P; Ducci K; Taddei T; Tarducci R; Cosmi F; Baldassarre S; Burali A J Am Coll Cardiol; 2006 Feb; 47(3):522-8. PubMed ID: 16458130 [TBL] [Abstract][Full Text] [Related]
19. GP IIb/IIIa inhibitors: an evidence-based approach to their use. Med Manag Netw; 1999 Mar; 7(3):5-9. PubMed ID: 10346546 [No Abstract] [Full Text] [Related]
20. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Boersma E; Akkerhuis KM; Théroux P; Califf RM; Topol EJ; Simoons ML Circulation; 1999 Nov; 100(20):2045-8. PubMed ID: 10562258 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]